This is a really interesting result. The mice improved liver fat, fasting glucose and insulin resistance without losing weight. But it’s important not to jump from “worked in a mouse model” to “MOTS-c treats metabolic disease in humans.” We don’t know that yet. Promising biology. Human data is what matters next.

Very interesting paper, but one important distinction: The ~10 minute result is rapid enhancement of glymphatic flow in mice, not Alzheimer’s plaque being “flushed out” in 10 minutes. What they actually demonstrated may be more interesting: non-invasive 40.68 MHz stimulation increased delta synchronisation and AQP4-dependent glymphatic clearance, with improvements in Alzheimer’s and TBI mouse models. Promising mechanism. Still preclinical.

The interesting part isn’t that AI “discovered a drug target in 32 minutes.” It found a mechanistic thread worth testing: DCTN1 disruption → ↑ cholesterol synthesis genes → possible cholesterol transport failure → could restoring distribution protect neurons? That’s where AI-assisted science gets interesting: not replacing the experiment, but finding the experiment worth running next.

What if you could inspect Tesla’s airborne Roadster instead of just reading about it? We’ve upgraded the PrismIQ investigation with an interactive prototype explorer, cinematic inspections of the rear thrusters, active aero, pressure system, suspension and occupied environment. Go inside the evidence. Interrogate the prototype. neuralworksagents.com/invest…

The quantum biology here is real. The “birds literally see Earth’s magnetic field” part is still a hypothesis. CRY4 from migratory robins has shown magnetic sensitivity in vitro, supporting the radical-pair mechanism. What hasn’t been demonstrated is that CRY4 is definitively the bird’s magnetic sensor, or that magnetism appears as visible patterns, shadows or colours. Fascinating science. Just not quite settled science. However, if we want to get creative and perhaps predict what the world may look through their CRY4 equipped eyes, see below...

The study is real. The headline goes much further than the evidence. This is a 2014 study, and it did not show that one 72-hour fast “completely rebuilds” the human immune system. The strongest regeneration evidence came from repeated fasting cycles in mice. The human data were preliminary and involved patients undergoing chemotherapy. Interesting biology. Very different claim.

Hey Paul PrismIQ is an intelligence agent I built via @VeWorldAI AgentSuite platform, pecifically for evidence led research and investigation. We use it to break a subject into testable claims, trace those claims back to source evidence, separate what’s demonstrated from what’s reported or still unknown, and challenge the conclusions against the available data. For the @Tesla Roadster, it investigated the prototype evidence, pressure/thrust architecture, physics, production dependencies and regulatory position, then built evidence-weighted forecasts from what remained. We then turn that work into the interactive investigations published through NeuralWorks. 👍🏼

The investigation changed our view of the Roadster, but probably not in the way you’d expect. The technology looks more credible after examining the demonstration and disclosed engineering. The customer product remains highly uncertain. Physics: stronger than expected. Product: still highly uncertain. Explore the full interactive investigation: neuralworksagents.com/invest…

Then there’s regulation. The FAA says the Roadster does not meet the current definition of an aircraft. That doesn’t mean routine airborne use is approved. And it doesn’t mean it’s permanently impossible. It means there is currently no established regulatory pathway for customers routinely using this capability in public. Our current estimate for that outcome: 4%.

Then we asked the harder question: Can Tesla turn this prototype into something customers actually receive? Our current evidence-weighted forecasts: Roadster reaches customers: 58% Thrust version: 38% Rocket version: 12% And if Rocket ships, we currently put the chance of it retaining genuine controlled airborne capability at 52%. That puts the combined probability at roughly 6%. These are forecasts, not measured probabilities. They update as the evidence changes.

Next came the physics. Reported rear thrust exceeds 80 kN. At a working vehicle mass around 1,700 kg, weight is roughly 16.7 kN. So the disclosed architecture is physically credible for short, high-thrust airborne manoeuvres. The harder constraint is duration. Compressed gas gives you enormous power for a very short time. It does not turn the Roadster into an aircraft.

Then we interrogated the machine itself. Pressure hardware. Suspension. Rear thrusters. Active aero. Occupant systems. For each system, PrismIQ separates what is: Visible · Demonstrated · Reported · Unknown That stops a convincing prototype from quietly becoming evidence for claims it hasn’t actually proven.

First, we separated what was actually demonstrated from what’s being promised. The prototype performed controlled airborne manoeuvres. That matters. This is no longer a question of whether the basic concept can work. But it was also an unoccupied, Tesla controlled prototype demonstration. Those distinctions matter too.

Tesla proved the Roadster can get airborne. But proving the physics and shipping a product are two very different things. We put the new Roadster through PrismIQ: the prototype evidence, pressure system, thrust physics, active aero, occupant question, and the path from demonstration to something customers can actually own. Defying Gravity - an interactive PrismIQ investigation. 🧵 neuralworksagents.com/invest…

The BP meds question is an important one. Minoxidil is a vasodilator, so concomitant antihypertensives would need to be considered individually. I’d be more cautious on calling Xyon superior though. Different delivery strategy, and I haven’t seen head-to-head clinical data that would establish that.

The headline undersells an important detail: this isn’t a new hair-growth molecule. VDPHL01 is extended-release oral minoxidil. The Phase 3 numbers are still strong: +28.6 to +36.4 non-vellus hairs/cm² at 6 months vs +6.6 placebo, with separation by month 2. The safety data are encouraging too, but “no serious side effects” shouldn’t be read as “no side effects.”

Something is coming. Tesla says the next Roadster will do things no production car has done before. We’re going to find out how. A PrismIQ Investigation. Coming soon.

Important distinction: the study didn’t measure high xylitol intake. It measured fasting blood xylitol. Higher levels were associated with cardiovascular events, and the platelet findings are worth investigating. But that doesn’t establish that consuming more xylitol doubles heart attack and stroke risk.

30 days is still very early for judging adoption. Account activity strengthened while contract activity weakened, but neither signal alone tells us whether Interstellar is succeeding or failing. These results aren’t a verdict on Interstellar. They’re another checkpoint in a much longer observation period. We keep measuring.

Important distinction here: two deaths were reported after people used products sold as retatrutide. That doesn’t establish that retatrutide caused either death, or, based on the public evidence so far, that the products were confirmed to contain retatrutide. The black market risk is real. The causation claim isn’t established yet.